Citius OncologyCTOR +4.19%10 Forward PE Ratio is 6.47 as of Jul. 06, 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 408 Drug Manufacturers companies, Citius Oncology ranks better than 93.38% on this metric.
Citius Oncology (NAS:CTOR) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Citius Oncology Forward PE Ratio Related Terms
Citius Oncology Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Citius Oncology's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Oncology Forward PE Ratio Chart
Citius Oncology Annual Data
Trend
2025-09
Forward PE Ratio
36.20
Citius Oncology Quarterly Data
2025-03
2025-06
2025-09
2025-12
Forward PE Ratio
1.55
90.20
36.20
22.60
CTOR vs INCR, TLPH, ETST: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Citius Oncology's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Citius Oncology (CTOR) has a Forward PE Ratio of 6.47 as of Jul. 06, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Citius Oncology and its competitors. According to the industry distribution chart, Citius Oncology ranks #27 out of 408 companies in the Drug Manufacturers industry, placing it in the top 6.6%.
Is Citius Oncology's Forward PE Ratio too high?
Citius Oncology's current Forward PE Ratio is 6.47. The Drug Manufacturers industry median Forward PE Ratio is 17.53. Citius Oncology's value of 6.47 is 63.1% below this industry median. Based on the distribution chart, Citius Oncology ranks #27 out of 408 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Forward PE Ratio compare to INCR and TLPH?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #27 out of 408 companies for Forward PE Ratio. This places Citius Oncology in the top 7% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 17.53. Citius Oncology's value of 6.47 is 63.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.53, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Oncology's current Forward PE Ratio of 6.47 is 63.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current Forward PE Ratio is 6.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Forward PE Ratio of 6.47. The current Forward PE Ratio is 6.47 and 63.1% below the Drug Manufacturers industry median of 17.53. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Forward PE Ratio is 6.47 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 